Optisol corneal storage medium.

We compared the safety and efficacy of Optisol (Chiron Ophthalmics, Irvine, California), a new corneal storage medium, with McCarey-Kaufman and Dexsol corneal storage media (Chiron Ophthalmics, Irvine, California) and K-Sol corneal storage medium (Cilco, Huntington, West Virginia). Optisol contains dextran, 2.5% chondroitin sulfate, vitamins, and precursors of adenosine triphosphate (adenosine, inosine, and adenine). In in vitro studies, rabbit and human corneas stored in Optisol were thinner after 12 to 14 days at 4 C than tissue stored in other media. Thymidine uptake showed increased mitotic activity in human corneal endothelial cells cultured in Optisol, compared to Dexsol. Specular microscopic fields showed larger are-as of visibly intact endothelial cells and ultrastructural examination disclosed fewer structural changes in endothelial cells stored in Optisol, compared to tissue stored in Dexsol. In vivo, no clinical signs of epithelial toxicity or histologic evidence of intraocular inflammation were observed in rabbit eyes in which Optisol drops were instilled four times a day for 14 days. Finally, 51 patients undergoing penetrating keratoplasty with tissue stored in Optisol for one to six days (mean, 3.6 days) were enrolled in an uncontrolled, open-label clinical study. The percentage of clear grafts (93%, 41 of 44 patients examined at three months; and 98%, 42 of 43 patients examined at six months) and endothelial cell loss (5.0% and 11.5% at three and six months, respectively) were comparable to data from previous studies that used tissue stored in other short-term and intermediate-term media. The results suggest that Optisol storage preserves corneal endothelial cells for up to two weeks at 4 C, thereby permitting flexibility in the use of donor tissue for corneal transplantation, and that Optisol storage yields thinner tissue, which may allow for more accurate evaluation and more effective surgical manipulation.